Skip to main content
SpringerLink
Log in

Progestagens and Corticosteroids in the Management Cancer Cachexia

  • Chapter
Cachexia and Wasting: A Modern Approach

  • 2120 Accesses

Abstract

Over the past few years, many authors have approached the problem of the treatment of cancer cachexia focusing on either the knowledge of the main pathogenetic events, or the outcomes of the treatment in terms of symptoms or improvement in quality of life [1] [8]. The relevance of clinical investigations of cancer anorexia-cachexia has epidemiological and clinical roots, considering that it is very frequent in advanced and terminal disease (up to 40% of patients with advanced disease, and more than 80% of terminal patients), and that its clinical manifestations often represent a source of great concern for both patients and relatives [1] [5]. The clinical approach to cancer anorexia-cachexia has been directed towards different targets, and it can be aetiological, pathogenetic or symptomatic according to the attention paid to tumour growth, the main pathogenetic events, or the clinical behaviour of the syndrome. However, it is mandatory to define both the biological and clinical rationale of the different therapeutic options, and the outcomes of every therapeutic approach, using an evidence-based model.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Laviano A, Meguid MM, Rossi-Fanelli F (2003) Cancer anorexia: clinical implications, pathogenesis and therapeutic strategies. Lancet Oncol 4:686–694

    Article  PubMed  CAS  Google Scholar 

  2. Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91

    Article  PubMed  Google Scholar 

  3. Nelson KA (2000) The cancer anorexia-cachexia syndrome. Semin Oncol 27:64–68

    PubMed  CAS  Google Scholar 

  4. Davis MP, Dickerson D (2000) Cachexia and anorexia: cancer’s covert killer. Support Care Cancer 8:180–187

    Article  PubMed  CAS  Google Scholar 

  5. Puccio M, Nathanson L (1997) The cancer cachexia syndrome. Semin Oncol 24:277–287

    PubMed  CAS  Google Scholar 

  6. Kotler DP (2000) Cachexia. Ann Intern Med 133:622–634

    PubMed  CAS  Google Scholar 

  7. Dunlop RJ, Camplell CW (2000) Cytokines and advanced cancer. J Pain Symptom Manage 20:214–232

    Article  PubMed  CAS  Google Scholar 

  8. Mantovani G, Macciò A, Massa E, Madeddu C (2001) Managing cancer-related anorexia/cachexia. Drug 61:499–514

    Article  CAS  Google Scholar 

  9. Jatoi A, Loprinzi CL (2002) Anorexia/weight loss. In: Berger AM, Portenoy RK, Weissman DE (eds) Principles and practice of palliative care and supportive oncology, 2nd edn. Lippincott Williams and Wilkins, Philadelphia, pp 169–177

    Google Scholar 

  10. Strasser F (2004) Pathophysiology of the anorexia/cachexia syndrome. In: Doyle D, Hanks G, Cherny N, Caiman K (eds) Oxford textbook of palliative medicine, 3rd edn. Oxford University Press, New York, pp 520–533

    Google Scholar 

  11. Rink TJ (1994) In search of a satietary factor. Nature 372:406–407

    Article  PubMed  CAS  Google Scholar 

  12. Spina M, Merlo-Pick E, Chan RKW et al (1996) Appetite suppressing effect of urocortin, a CRFrelated neuropeptide. Science 273:1561–1564

    Article  PubMed  CAS  Google Scholar 

  13. Beck SA, Mulligan HD, Tisdale MJ (1990) Lipolytic factors associated with murine and human cancer cachexia. J Natl Cancer Inst 82:1922–1926

    Article  PubMed  CAS  Google Scholar 

  14. Todorov P, Cariuk P, McDevitt T et al (1996) Characterisation of a cancer cachectic factor. Nature 379:739–742

    Article  PubMed  CAS  Google Scholar 

  15. Khan S, Tisdale MJ (1999) Catabolism of adipose tissue by a tumor produced lipid mobilising factor. Int J Cancer 80:444–447

    Article  PubMed  CAS  Google Scholar 

  16. Hussey HJ, Tisdale MJ (1999) Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. Br J Cancer 80:1231–1235

    Article  PubMed  CAS  Google Scholar 

  17. Belisario JE, Katz M, Chenker E et al (1991) Bioactivity of skeletal muscle proteolysis inducing factor in the plasma proteins from cancer patients with weight loss. Br J Cancer 63:705–710

    Google Scholar 

  18. Todorov PT, Deacon M, Tisdale MJ (1997) Structural analysis of a tumor produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 272:12279–12288

    Article  PubMed  CAS  Google Scholar 

  19. Cariuk P, Lorite MJ, Todorov PT et al (1997) Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 6:606–613

    Google Scholar 

  20. Lorite MJ, Thomson MG, Drake JL et al (1998) Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 78:850–856

    PubMed  CAS  Google Scholar 

  21. Lorite MJ, Cariuk P, Tisdale MJ (1997) Induction of muscle protein degradation by a tumor factor. Br J Cancer 76:1035–1040

    PubMed  CAS  Google Scholar 

  22. Wigmore SJ, Todorov PT, Barber MD et al (2000) Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 87:53–58

    Article  PubMed  CAS  Google Scholar 

  23. Groundwater P, Beck SA, Barton C et al (1990) Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br J Cancer 62:816–821

    PubMed  CAS  Google Scholar 

  24. Cahlin C, Korner A, Axelsson H et al (2000) Experimental cancer cachexia: the role of hostderived cytokines interleukin-6, interleukin-12, interferon-gamma and tumor necrosis factor alpha evaluated in gene knockout bearing mice on C57B1 background and eicosapentaenoic-dependent cachexia. Cancer Res 60:5488–5493

    PubMed  CAS  Google Scholar 

  25. Smith HJ, Lorite MJ, Tisdale MJ (1997) Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblast: modulation by eicosapentaenoic acid. Cancer Res 59:5507–5513

    Google Scholar 

  26. Beck SA, Smith KL, Tisdale MJ (1991) Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51:6089–6093

    PubMed  CAS  Google Scholar 

  27. Nakashima J, Tachibana M, Ueno M et al (1998) Association between tumor necrosis factor in serum and cachexia in patients with prostatic cancer. Clin Cancer Res 4:1743–1748

    PubMed  CAS  Google Scholar 

  28. Soda K, Kawakami M, Kashii A et al (1995) Manifestations of cancer cachexia induced by colon adenocarcinoma are not fully ascribable to interleukin 6. Int J Cancer 28:332–336

    Article  Google Scholar 

  29. Tisdale MJ (1998) New cachectic factor. Curr Opin Clin Nutr Metab Care 1:253–256

    Article  PubMed  CAS  Google Scholar 

  30. Albrect JT, Canada TW (1996) Cachexia and anorexia in malignancy. Hematol Oncol Clin North Am 10:791–800

    Article  Google Scholar 

  31. Naguchi Y, Yoshikawa T, Matsumoto A et al (1996) Are cytokines possible mediators of cancer cachexia? Surg Today 26:467–475

    Article  Google Scholar 

  32. Nomura K, Noguchi Y, Yoshikawa T et al (1997) Plasma interleukin-6 is not a mediator of changes in lipoprotein lipase activity in cancer patients. Hepatogastroenterology 44:1519–1526

    PubMed  CAS  Google Scholar 

  33. Argiles GM, Lopez-Soriano FJ (1999) The role of cytokines in cancer cachexia. Med Res Rev 19:223–248

    Article  PubMed  CAS  Google Scholar 

  34. Shibata M, Takekawa M (1999) Increased serum concentrations of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer. Oncology 56:54–58

    Article  PubMed  CAS  Google Scholar 

  35. Bossola M, Muscaritoli M, Bellantone R et al (2000) Serum tumor necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest 30:1107–1112

    Article  PubMed  CAS  Google Scholar 

  36. Maltoni M, Fabbri L, Nanni O et al (1997) Serum levels of tumor necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 5:130–135

    Article  PubMed  CAS  Google Scholar 

  37. Mantovani G (2000) Cachexia and anorexia. Support Care Cancer 8:506–507

    Article  PubMed  CAS  Google Scholar 

  38. Espat NJ, Copeland EM, Moldawer LL et al (1994) Tumor necrosis factor and cachexia: a current perspective. Surg Oncol 3:255–262

    Article  PubMed  CAS  Google Scholar 

  39. McNamara MJ, Alexander HR, Norton JA (1992) Cytokines and their role in the pathophysiology of cancer cachexia. JPEN J Parenter Enterai Nutr 16(Suppl 6):50–53

    Google Scholar 

  40. Moldawer LL, Rogy MA, Lowry SF et al (1992) The role of cytokines in cancer cachexia. JPEN J Parenter Enterai Nutr 16:43–49

    Article  Google Scholar 

  41. Plata-Salaman CR (1992) Central nervous system mechanism contributing to the cachexia-anorexia syndrome. Nutrition 16:43–49

    Google Scholar 

  42. Mantovani G, Macciò A, Lai P et al (1998) Cytokines involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxy-progesterone acetate on cytokine down-regulation and improvement of clinical symptoms. Crit Rev Oncog 9:99–106

    PubMed  CAS  Google Scholar 

  43. Mantovani G, Macciò A, Esu S et al (1997) Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 33:602–607

    Article  PubMed  CAS  Google Scholar 

  44. Mantovani G, Macciò A, Lai P et al (1998) Cytokine activity in cancer related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25(Suppl 6):45–52

    PubMed  CAS  Google Scholar 

  45. Peuckmann V, Fisch M, Bruera E (2000) Potential novel uses of thalidomide: focus on palliative care. Drugs 60:273–292

    Article  PubMed  CAS  Google Scholar 

  46. Schimdt H, Rush B, Simonian G (1996) Thalidomide inhibits TNF response and increases survival following endotoxins in rats. J Surg Res 63:143–146

    Article  Google Scholar 

  47. Bruera E, Neumann C, Pitukskin E et al (1999) Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 10:857–859

    Article  PubMed  CAS  Google Scholar 

  48. Lissoni P, Paolorossi F, Tancini G et al (1996) Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 32A:1340–1343

    Article  PubMed  CAS  Google Scholar 

  49. Neri B, DeLeonardis V, Gemelli MT et al (1998) Melatonin as biological response modifier in cancer patients. Anticancer Res 18:1329–1332

    PubMed  CAS  Google Scholar 

  50. Tisdale M (1996) Inhibition of lypolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 12(Suppl 1):531–533

    Google Scholar 

  51. DeDeckerre E (1999) Possible beneficial effect of fish and fish N-3 polyunsaturated fatty acids in breast and colorectal cancer. Eur J Cancer Prev 80:1231–1235

    Google Scholar 

  52. Barber M, Ross J, Vossa C et al (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81:80–86

    Article  PubMed  CAS  Google Scholar 

  53. Moertel CG, Schutt AJ, Reitemeir RJ et al (1974) Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607–1609

    Article  PubMed  CAS  Google Scholar 

  54. Ettingen AB, Portenoy RK (1988) The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 3:99–103

    Article  Google Scholar 

  55. Lissoni P, Brivio F, Ardizzoia A et al (1993) Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 79:401–404

    PubMed  CAS  Google Scholar 

  56. McMillian DC, O’Gorman P, Fearon KCF et al (1997) A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 76:788–790

    Google Scholar 

  57. Cerchietti LCA, Navigante AH, Peluffo GD et al (2004) Effects of celecoxib, medroxyprogesterone and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85–95

    Article  PubMed  CAS  Google Scholar 

  58. Arteaga CL, Moulder SL, Yakes M (2002) HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 29(Suppl 11):4–10

    Article  PubMed  CAS  Google Scholar 

  59. Pegram MD, Reese DM (2002) Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 29(Suppl 11):29–37

    Article  PubMed  CAS  Google Scholar 

  60. Ligibel JA, Winer EP (2002) Trastuzumab/chemotherapy combination in metastatic breast cancer. Semin Oncol 29(Suppl 11):38–43

    Article  PubMed  CAS  Google Scholar 

  61. Ritter CA, Arteaga CL (2003) The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30(Suppl 1):3–11

    Article  PubMed  CAS  Google Scholar 

  62. Cella D (2003) Impact of ZD1839 on non small cell lung cancer related symptoms as measured by the functional assessment of cancer therapy lung scale. Semin Oncol 30(Suppl 1):39–48

    Article  PubMed  CAS  Google Scholar 

  63. Douglass EC (2003) Development of ZD1839 in colorectal cancer. Semin Oncol 30(Suppl 6):17–22

    Article  PubMed  CAS  Google Scholar 

  64. Grunwald V, Hidalgo M (2003) Development of the epidermal growth factor receptor inhibitor OSI-774. Semin Oncol 30(Suppl 6):23–31

    Article  PubMed  CAS  Google Scholar 

  65. Swaton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27–36

    Article  CAS  Google Scholar 

  66. Johnson P, Glennie M (2003) The mechanism of action of rituximab in the elimination of tumor cells. Semin Oncol 30(Suppl 2):3–8

    Article  PubMed  CAS  Google Scholar 

  67. Tassinari D, Sartori S, Maltoni M et al (2004) Target therapies in palliative care: from a clinical to a biological approach. J Pain Symptom Manage 28:195–197

    Article  PubMed  Google Scholar 

  68. Rubin H (2003) Cancer cachexia: its correlations and causes. Proc Natl Acad Sci USA 100:5384–5389

    Article  PubMed  CAS  Google Scholar 

  69. Anonymous (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. Amercian Society of Clinical Oncology. J Clin Oncol 14:671–679

    Google Scholar 

  70. Kaasa S, Loge JH (2003) Quality of life in palliative care: principles and practice. Palliat Med 17:11–20

    Article  PubMed  Google Scholar 

  71. Kaasa S, Loge JH (2002) Quality of life assessment in palliative care. Lancet Oncol 3:175–182

    Article  PubMed  Google Scholar 

  72. Cochrane AL (1972) Effectiveness and efficiency: random reflection on health services. Royal Society of Medicine, London

    Google Scholar 

  73. Haynes B (1999) Can it work? Does it work? Is it worth it? BMJ 319:652–653

    PubMed  CAS  Google Scholar 

  74. Tassinari D (2003) Surrogate end point of quality of life assessment: have we really found what we are looking for? Health Qual Life Outcomes 1:71

    Article  PubMed  Google Scholar 

  75. Tassinari D, Poggi B, Fantini M et al (2003) Can we really consider quality of life as an outcome of palliative care? J Pain Symptom Manage 26:886–887

    Article  PubMed  Google Scholar 

  76. Tassinari D, Panzini I, Sartori S, Ravaioli A (2003) Surrogate outcomes in quality of life research: where we will end up? J Clin Oncol 21:1894–1895

    Article  PubMed  Google Scholar 

  77. Tassinari D, Panzini I, Ravaioli A et al (2002) Quality of life at the end of life: how is the solution far away? J Clin Oncol 20:1704–1705

    PubMed  Google Scholar 

  78. Hwang SS, Chang VT, Fairclough DL et al (2003) Longitudinal quality of life in advanced cancer patients: pilot study results from a VA medical center. J Pain Symptom Manage 25:225–235

    Article  PubMed  Google Scholar 

  79. Goodwin DM, Higginson IJ, Myers K et al (2003) Effectiveness of palliative day care in improving pain, symptom control and quality of life. J Pain Symptom Manage 25:202–212

    Article  PubMed  Google Scholar 

  80. Cook DJ, Guyatt GH, Laupacis A, Sackett DL (1992) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102(Suppl 4):305S–311S

    PubMed  CAS  Google Scholar 

  81. Harbour R, Miller J (2001) A new system for grading recommendations in evidence based guidelines. BMJ 323:334–336

    Article  PubMed  CAS  Google Scholar 

  82. Tassinari D, Maltoni M, Amadori D (2002) Prediction of survival in terminally ill cancer patients: why we cannot avoid an evidence-based palliative medicine. Ann Oncol 13:1322–1323

    Google Scholar 

  83. Kaasa S, De Conno F (2001) Palliative care research. Eur J Cancer 37(Suppl 8):153S–159S

    Article  Google Scholar 

  84. Henriksen H, Gamborg H, Leikersfeldt G (2003) Corticosteroids in palliation of preterminal and terminal cancer patients. Evidence or empiricism? Ugeskr Laeger 165:3913–3917

    PubMed  Google Scholar 

  85. Moertel C, Schutt AG, Reiteneier RJ et al (1974) Corticosteroid therapy of pre-terminal gastrointestinal cancer. Cancer 33:1607–1609

    Article  PubMed  CAS  Google Scholar 

  86. Willox J, Corr J, Shaw J et al (1984) Prednisolone as an appetite stimulant in patients with cancer. BMJ 288:27

    Article  PubMed  CAS  Google Scholar 

  87. Bruera E, Roca E, Cedaro L et al (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double blind study. Cancer Treat Rep 69:751–754

    PubMed  CAS  Google Scholar 

  88. Robustelli della Cuna G, Pellegrini A, Piazzi M (1989) Effect of methylprednisolone sodium succinate on quality of life in pre-terminal cancer patients: a placebo controlled multicenter study. Eur J Cancer Clin Oncol 25:1823–1829

    Article  Google Scholar 

  89. Popiela T, Lucchi R, Giongo F (1989) Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 25:1823–1829

    Article  PubMed  CAS  Google Scholar 

  90. Barnes EA, Bruera E (2002) Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 12(5):424–428

    Article  PubMed  CAS  Google Scholar 

  91. Bruera E, Neumann CM (1998) Management of specific symptom complexes in patients receiving palliative care. CMAJ 158:1717–1726

    PubMed  CAS  Google Scholar 

  92. Bruera ED, MacEachern TJ, Spachynski KA et al (1994) Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 74:3204–3211

    Article  PubMed  CAS  Google Scholar 

  93. Watanabe S, Bruera E (1994) Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 9:442–445

    Article  PubMed  CAS  Google Scholar 

  94. Bruera E, Sweeney C (2004) Pharmacological interventions in cachexia and anorexia. In: Doyle D, Hanks G, Cherny N, Caiman K (eds) Oxford textbook of palliative medicine, 3rd edn. Oxford University Press, New York, pp 552–560

    Google Scholar 

  95. Maltoni M, Nanni O, Scarpi E et al (2001) High-dose progestins for the treatment of cancer anorexiacachexia syndrome: a systematic review of randomized clinical trials. Ann Oncol 12:289–300

    Article  PubMed  CAS  Google Scholar 

  96. Lopez AP, Roquè-i-Figuls M, Urrutia Cuchi G et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 27:360–369

    Article  CAS  Google Scholar 

  97. Bruera E, Ernst S, Hagen N et al (1998) Effectiveness of megestrol acetate in patients with advanced cancer: a randomized double blind, crossover study. Cancer Prev Control 2:74–78

    PubMed  CAS  Google Scholar 

  98. De Conno F, Martini C, Zecca E et al (1998) Megestrol acetate for anorexia in patients with faradvanced cancer: a double-blind controlled clinical trial. Eur J Cancer 34:1705–1709

    Article  PubMed  Google Scholar 

  99. Simons JPFHA, Aaronson NK, Vansteenkiste JF et al (1996) Effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicentric study. J Clin Oncol 14:1077–1084

    PubMed  CAS  Google Scholar 

  100. Vedell C, Segui MA, Gimenez-Arnau JM et al (1998) Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 21:347–351

    Article  Google Scholar 

  101. Beller E, Tattersall M, Lumley T et al (1997) Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian megestrol acetate cooperative study group. Ann Oncol 8:277–283

    Article  PubMed  CAS  Google Scholar 

  102. Kornek GV, Schenk T, Ludwig H et al (1996) Placebo-controlled trial of medroxyprogesterone acetate in gastrointestinal malignancies and cachexia. Onkologie 19:164–168

    Article  Google Scholar 

  103. Rowland KM, Loprinzi CL, Shaw EG et al (1996) Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 14:135–141

    PubMed  CAS  Google Scholar 

  104. Tchekmedyian NS, Hickman M, Siau J et al (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268–1274

    Article  PubMed  CAS  Google Scholar 

  105. Westman G, Bergman B, Albertsson M et al (1999) Megestrol acetate in advanced progressive hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled randomised multicentre trial. Eur J Cancer 35:586–595

    Article  PubMed  CAS  Google Scholar 

  106. Loprinzi CL, Michalak D, Schaid DJ et al (1993) Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 11:762–767

    PubMed  CAS  Google Scholar 

  107. Feliu J, Gonzalez-Baron M, Berrocal A et al (1992) Usefulness of megestrol acetate in cancer cachexia and anorexia. Am J Clin Oncol 15:436–440

    Article  PubMed  CAS  Google Scholar 

  108. Schmoll E (1992) Risks and benefit of various therapies for cancer anorexia. Oncology 49:43–45

    Article  PubMed  Google Scholar 

  109. Downer S, Joel S, Allbright A et al (1993) A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 67:1102–1105

    PubMed  CAS  Google Scholar 

  110. Loprinzi CL, Ellison NM, Schaid DJ et al (1990) Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127–1132

    Article  PubMed  CAS  Google Scholar 

  111. Neri B, Garosi VL, Intini C (1997) Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs 8:459–465

    Article  PubMed  CAS  Google Scholar 

  112. Bruera E, MacMillan K, Kuehn N et al (1990) A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer. Cancer 66:1279–1282

    Article  PubMed  CAS  Google Scholar 

  113. Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group Study. J Clin Oncol 20:567–573

    Article  PubMed  CAS  Google Scholar 

  114. Cella D, Chang CH, Lai JS et al (2002) Advances in quality of life measurements in oncology patients. Semin Oncol 29(Suppl 8):60–68

    Article  PubMed  Google Scholar 

  115. Loprinzi CL, Kugler JW, Sloan JA et al (1999) A randomized comparison of megestrol acetate versus dexamethasone, versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 17:3299–3306

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Davide Tassinari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Maltoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, University of Cagliari, Cagliari, Italy

    Giovanni Mantovani

  2. Department of Clinical Cardiology, Imperial College, NHLI, London, UK

    Stefan D. Anker

  3. Department of Cardiology Charité, Applied Cachexia Research, Campus Virchow-Klinikum, Berlin, Germany

    Stefan D. Anker

  4. Department of Behavioral Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    Akio Inui

  5. GRECC, VA Medical Center and Division of Geriatric Medicine, Saint Louis University, St. Louis, MO, USA

    John E. Morley

  6. Department of Clinical Medicine, University of Rome, La Sapienza, Rome, Italy

    Filippo Rossi Fanelli

  7. Department of Infectious Diseases, IRCCS S.Matteo Polyclinic, University of Pavia, Pavia, Italy

    Daniele Scevola

  8. Bone Marrow and Blood Stem Cell Transplantation Program, Center for Lymphoma and Myeloma, New York Presbyterian Hospital/Weill Medical Center, New York, NY, USA

    Michael W. Schuster

  9. Department of Medicine-Geriatrics, University of New York at Stony Brook VAMC, Northport, NY, USA

    Shing-Shing Yeh

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Tassinari, D., Maltoni, M. (2006). Progestagens and Corticosteroids in the Management Cancer Cachexia. In: Mantovani, G., et al. Cachexia and Wasting: A Modern Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-0552-5_64

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-0552-5_64

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0471-9

  • Online ISBN: 978-88-470-0552-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation